Fulgent Genetics has acquired Fulgent Pharma
This exciting consolidation allows Fulgent to forge a path toward fully integrated precision medicine offerings with an oncology focus.
Technology & Developments
Using its library of patented polymers, Fulgent Pharma has
successfully nanoencapsulated poorly soluble drugs
to improve their efficacy and reduce their toxicity

Why Nanoencapsulation is Necessary

Nanoencapsulation of poorly soluble drugs with non-toxic, non-immunogenic, and biocompatible polymers has successfully enhanced drug delivery, safety, and effectiveness. Fulgent Pharma combines its patented nanoencapsulation technology with both established and early-discovery anti-cancer drugs to create new therapies with lower toxicity, targeted delivery, and enhanced tumor reduction.

By surrounding the unmodified, poorly soluble drug molecules within a capsule of polymeric molecules, nanoencapsulated drugs become much more water soluble. The encapsulating polymers protect the drug from degradation and clearance in acidic environments, binding proteins, digesting enzymes, and in vivo precipitation. Biodistribution and bioavailability to the target tissues and cells are significantly improved, while toxicity is reduced.

Nanoencapsulated Drugs - fulgent pharma

Nanoencapsulation Developments at Fulgent Pharma

Based on our extensive experience with many poorly soluble drugs, we can structurally fine-tune our polymers for maximum efficacy of each insoluble drug’s therapeutic performance. Our nanoencapsulation technology is ideal for formulating poorly soluble drugs into soluble surfactant- and solvent-free amorphous drug entities for IV injection.

Paclitaxel is a known, poorly soluble drug. Through nanoencapsulation, we have made the nanoencapsulated paclitaxel (FID-007) soluble in water for IV injection. Efficacy studies using FID-007 have shown tumor reduction in breast, ovarian, lung, leukemia, pancreatic, gastric and bladder cancers in a mouse xenograft model.